Public Release: 

Insilico to present the advances in AI for pharma industry at AI Transforming Pharma R&D Congress

InSilico Medicine, Inc.


IMAGE: Insilico Medicine will present at the Artificial Intelligence: Transforming Pharma R&D Congress in Boston view more 

Credit: Insilico Medicine

Thursday, February 15th, 2018, Baltimore, MD - Insilico Medicine, a Baltimore-based company specializing in the application of artificial intelligence for drug discovery, biomarker development and aging research, will be presented at the Artificial Intelligence: Transforming Pharma R&D Congress, 21-22 February 2018, organized by Kisaco Research.

Alex Zhavoronkov, Founder and CEO of Insilico Medicine, will present the latest advances of artificial intelligence for drug discovery and cover the successful cases and practical challenges in integrating of AI into the pharmaceutical sector at the panel discussion "How to implement an Artificial Intelligence strategy into your corporation?".

"Kisaco Research Artificial Intelligence: Transforming Pharma R&D Congress brings together many of the thought leaders in the field and presents a very thought-through and balanced program. 2017 was the year when the pharmaceutical industry started treating AI seriously and this year we see deeper penetration and broader adoption of the modern AI techniques by the pharmaceutical and biotechnology companies alike", said Alex Zhavoronkov, PhD, the founder and CEO of Insilico Medicine, Inc.

Artificial Intelligence: Transforming Pharma R&D Congress offers to participants the first-hand experience from the prominent industry speakers showcasing how AI is transforming pharma R&D. The conference provides the real-life cases of AI applications for the pharmaceutical sector, guidance from pharma leaders on how to incorporate an AI strategy into the organizations and insights into current partnerships between pharmaceutical and biotech companies and AI solution providers.

Insilico Medicine is regularly publishing many "firsts" and proofs of concepts in the application of deep learning to drug discovery and biomarker development. It was the first to apply the deep generative adversarial networks (GANs) to the generation of new molecular structures with specified parameters and published seminal papers in Oncotarget and Molecular Pharmaceutics. Another paper published in Molecular Pharmaceutics in 2016 and demonstrated the proof of concept of the application of deep neural networks for predicting the therapeutic class of the molecule using the transcriptional response data, received the American Chemical Society Editors' Choice Award. One of the recent papers published in November 2017 described the application of the next-generation AI and blockchain technologies to return the control over personal data back to the individual. The latest paper published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients.


For further information, images or interviews, please contact:

Contact: Qingsong Zhu, PhD

Official Conference Website:

About Insilico Medicine, Inc

Insilico Medicine, Inc. is an artificial intelligence company headquartered at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore, with R&D and management resources in Belgium, Russia, UK, Taiwan and Korea sourced through hackathons and competitions.

The company utilizes advances in genomics, big data analysis, and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI and Aging.AI and operates Chemistry.AI intended to capture the tacit knowledge of medicinal chemists.

Through a partnership with the BitFury Group, the company is working on a range of AI solutions for blockchain to help return the power over life data back to the individual. The company raised venture capital and partnered with Juvenescence Limited, a holding company focused on longevity biotechnology. The company aspires to become the "Bell Labs" for artificial intelligence and associated technologies for healthcare and longevity biotechnology and commercialize its research by forming subsidiaries around the specific technologies and licensing the intellectual property, molecules and data to the biotechnology and pharmaceutical companies. In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. Brief company video:

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.